



If you would like to refer a patient for a PSMA PET/CT scan, please complete this form and send it to SMIL, please also include the following to expedite schedule and authorization:  Clinicals  Recent Imaging Reports  2 Most Recent PSA Results  Script/Order

Please select an imaging agent:  F 18 Posluma  F 18 Pylarify  Ga 68 PSMA-11 Illuccix  Ga 68 PSMA-11 Locametz

Patient Name: \_\_\_\_\_ \*Today's Date: \_\_\_\_\_

Patient DOB: \_\_\_\_\_ Patient Day Phone / Cell: \_\_\_\_\_

Primary Insurance: \_\_\_\_\_ Subscriber ID: \_\_\_\_\_ Prior Auth#: \_\_\_\_\_

Secondary Insurance: \_\_\_\_\_ Subscriber ID: \_\_\_\_\_ Prior Auth#: \_\_\_\_\_

**Specific Reason for PSMA PET Study**

**Initial Staging** - for detection of suspected metastasis in patients with newly diagnosed prostate cancer who are candidates for initial definitive therapy.

\*Please see NCCN guidelines for initial Risk Stratification and Staging Workup (below)

**Unfavorable – Intermediate** (check all that apply)

- cTaB-cT2c  PSA 10-20
- Grade Group 3  ≥ 50% Positive Core Biopsies

**High Risk**

- cT3a  PSA > 20
- Grade Group 4 or Grade Group 5

**Very High Risk**

- cT3b-cT4  Primary Gleason Pattern 5
- Grade Group 4 or Grade Group 5
- > 4 Cores with Grade Group 4 or 5

**Suspected Recurrence** - previously treated prostate cancer based on elevated PSA

Prior Treatment (check all that apply)

- Prostatectomy
- Radiation
- Chemotherapy
- ADT
- Other (specify): \_\_\_\_\_

Lab Work

PSA Nadir After Treatment: \_\_\_\_\_

Current PSA: \_\_\_\_\_

Date: \_\_\_\_\_

PSA Doubling Time (if applicable): \_\_\_\_\_

Date of Diagnosis \_\_\_\_\_ Baseline PSA \_\_\_\_\_ Gleason Score \_\_\_\_\_  
Clinical T-Score \_\_\_\_\_ Positive Cores \_\_\_\_\_ %

Signature of Provider verifying patient status above: \_\_\_\_\_

**ICD-10 Code(s)** Check all that apply

Code	Description
C61	Malignant neoplasm of prostate
Z79.82	Secondary malignant neoplasm of genital organ must be billed accompanied by C61
Z19.1	Hormone sensitive malignancy must be billed accompanied by C61
Z19.2	Hormone resistant malignancy must be billed accompanied by C61
Z85.46	Personal history of malignant neoplasm of prostate must be billed accompanied by C61
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
Other	

**NCCN Guidelines Version 1.2023 Prostate Cancer INITIAL RISK STRATIFICATION AND STAGING WORKUP FOR CLINICALLY LOCALIZED DISEASES**

Risk Group	Clinical/Pathologic Features See Staging (ST-1)		Additional Evaluation <sup>h,i</sup>	Initial Therapy
Very low <sup>f</sup>	Has all of the following: • cT1c • Grade Group 1 • PSA <10 ng/mL • Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core <sup>g</sup> • PSA density <0.15 ng/mL/g		• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5)	See PROS-3
Low <sup>f</sup>	Has all of the following but does not qualify for very low risk: • cT1-cT2a • Grade Group 1 • PSA <10 ng/mL		• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5)	See PROS-4
Intermediate <sup>f</sup>	Favorable intermediate	Has all of the following • 1 IRF • Grade Group 1 or 2 • <50% biopsy cores positive (eg, <6 of 12 cores) <sup>g</sup>	• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5)	See PROS-5
		Unfavorable intermediate	Has one or more of the following: • 2 or 3 IRFs • Grade Group 3 • ≤50% biopsy cores positive (eg, ≤6 of 12 cores) <sup>g</sup>	Bone and soft tissue imaging <sup>i,k</sup> • If regional or distant metastases are found, see PROS-8 or PROS-12
High	Has no very-high-risk features and has exactly one high-risk feature: • cT3a OR • Grade Group 4 or Grade Group 5 OR • PSA >20 ng/mL		Bone and soft tissue imaging <sup>i,k</sup> • If regional or distant metastases are found, see PROS-8 or PROS-12	See PROS-7
Very high	Has at least one of the following: • cT3b-cT4 • Primary Gleason pattern 5 • 2 or 3 high-risk features • >4 cores with Grade Group 4 or 5		Bone and soft tissue imaging <sup>i,k</sup> • If regional or distant metastases are found, see PROS-8 or PROS-12	See PROS-7